Scholarlink

Background <p>Primary Vaginal Melanoma (PVM) is a rare and highly aggressive malignancy, accounting for only 0.3–0.8% of all female melanomas, with an extremely poor prognosis.</p> Objectives <p>This study aims to present the diagnostic process, surgical management, and postoperative chemotherapy options in a patient initially diagnosed with vaginal neuroendocrine carcinoma, later confirmed to have PVM. Additionally, we provide a systematic review to enhance awareness of PVM, reduce misdiagnosis, and improve early detection.</p> Methods <p>A systematic review of the literature was conducted, and a case report was analyzed.</p> Results <p>A total of 89 publications were reviewed, summarizing the various treatment strategies and survival outcomes for PVM. In the reported case, postoperative pathology confirmed the diagnosis of PVM, differentiating it from primary vaginal neuroendocrine carcinoma. The treatment involved partial vaginal excision and removal of lesions from the posterior vaginal wall, followed by adjuvant chemotherapy with temozolomide and cisplatin.</p> Conclusion <p>PVM is highly malignant with a poor prognosis, and surgical resection remains the primary treatment modality; however, its efficacy is limited. While chemotherapy may benefit some patients, the five-year survival rate ranging from 5 to 25%. Therefore, the development of novel therapeutic strategies is crucial. Recent advancements in immunotherapy and targeted therapies targeting BRAF/KIT mutations show promise, but standardized diagnostic and treatment protocols are still lacking. Future multicenter, long-term studies are needed to develop individualized treatment plans based on molecular profiling, providing an evidence-based approach to optimize diagnostic strategies and improve survival rates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in the diagnosis and treatment of primary malignant melanoma of the vagina- a case presentation and systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Chengbin Lu,
  • Die Fan,
  • Yu Xiong,
  • Xiaoxia Jiang,
  • Jiangsha Li,
  • Ping Yang,
  • Yuanlong Shi,
  • Hongmei Li,
  • Zheng Li

摘要

Background

Primary Vaginal Melanoma (PVM) is a rare and highly aggressive malignancy, accounting for only 0.3–0.8% of all female melanomas, with an extremely poor prognosis.

Objectives

This study aims to present the diagnostic process, surgical management, and postoperative chemotherapy options in a patient initially diagnosed with vaginal neuroendocrine carcinoma, later confirmed to have PVM. Additionally, we provide a systematic review to enhance awareness of PVM, reduce misdiagnosis, and improve early detection.

Methods

A systematic review of the literature was conducted, and a case report was analyzed.

Results

A total of 89 publications were reviewed, summarizing the various treatment strategies and survival outcomes for PVM. In the reported case, postoperative pathology confirmed the diagnosis of PVM, differentiating it from primary vaginal neuroendocrine carcinoma. The treatment involved partial vaginal excision and removal of lesions from the posterior vaginal wall, followed by adjuvant chemotherapy with temozolomide and cisplatin.

Conclusion

PVM is highly malignant with a poor prognosis, and surgical resection remains the primary treatment modality; however, its efficacy is limited. While chemotherapy may benefit some patients, the five-year survival rate ranging from 5 to 25%. Therefore, the development of novel therapeutic strategies is crucial. Recent advancements in immunotherapy and targeted therapies targeting BRAF/KIT mutations show promise, but standardized diagnostic and treatment protocols are still lacking. Future multicenter, long-term studies are needed to develop individualized treatment plans based on molecular profiling, providing an evidence-based approach to optimize diagnostic strategies and improve survival rates.